會(huì)員.png)
15
SK-MEL-1 細(xì)胞，人皮膚黑色素瘤細(xì)胞
| ATCC® Number: | HTB-67™ | Price: | |
| Designations:SK-MEL-1Depositors:G Trempe, LJ OldBiosafety Level:1Shipped:frozenMedium & Serum:See PropagationGrowth Properties:suspensionOrganism:Homo sapiens SK-MEL-1 細(xì)胞，人皮膚黑色素瘤細(xì)胞Source:Organ: skin Disease: malignant melanoma Derived from metastatic site: lymphatic systemCellular Products:melaninPermits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. Restrictions:The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; (212) 717-3439.Applications:Electron microscopy revealed pigment granules relating both to synthesis and to phagocytosis. Antibody to this line was detected in 63% of patients with malignant melanoma and in 10% of patients with other diseases.Tumorigenic:YesAntigen Expression:Blood Type A; Rh+DNA Profile (STR):Amelogenin: X,Y CSF1PO: 12,13 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 12 THO1: 6 TPOX: 11 vWA: 16,17Isoenzymes:AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1-2 PGM1, 1 PGM3, 1Age:29 yearsGender:maleEthnicity:CaucasianComments:F. Oettgen and associates isolated this line using cells obtained from the thoracic duct of a patient with widespread and rapidly progressing malignant melanoma. Electron microscopy revealed pigment granules relating both to synthesis and to phagocytosis. Antibody to this line was detected in 63% of patients with malignant melanoma and in 10% of patients with other diseases.Propagation:ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.Temperature: 37.0°CSubculturing:Medium Renewal: 2 to 3 times per week Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 1 X 10 exp5 cells/ml and maintain at 2 X 10 exp5.Preservation:Culture medium, 95%; DMSO, 5%Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003recommended serum:ATCC 30-2020References:1117: Oettgen HF, et al. Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. J. Natl. Cancer Inst. 41: 827-843, 1968. PubMed: 487957822536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 83387122539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 32708022816: Giraldo G, et al. Human sarcomas in culture. Foci of altered cells and a common antigen; induction of foci and antigen in human fibroblast cultures by filtrates. J. Exp. Med. 133: 454-478, 1971. PubMed: 432944723256: Carey TE, et al. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA 73: 3278-3282, 1976. PubMed: 106761932488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241 | |||
